Nanoparticle/siRNA-based therapy strategies in glioma: which nanoparticles, which siRNAs?
Nanoparticle/siRNA-based therapy strategies in glioma: which nanoparticles, which siRNAs?
复制标题
DOI：
10.2217/nnm-2017-0230
复制
发表时间：
2018-01-01
期刊：
影响因子：
5.5
通讯作者：
Koegel, Donat
中科院分区：
文献类型：
--
作者：
Aigner, Achim;Koegel, Donat
纳米药物允许传递小干扰RNA(SiRNAs)，否则几乎不适合作为诱导RNA干扰(RNAi)的治疗药物。在基于siRNA的胶质瘤体内治疗的临床前研究中，人们探索了各种纳米颗粒系统、给药途径和靶基因。还描述了通过功能化纳米颗粒与配基进行靶向传递以跨越血脑屏障和/或增强靶细胞转染性。本文重点介绍了近10年来纳米颗粒的研究进展，综述了纳米颗粒系统在脑胶质瘤中的应用，以及临床前的体内研究。此外，它还讨论了各种靶基因，并强调了在靶基因选择和联合治疗方面有前景的策略。
Nanomedicines allow for the delivery of small interfering RNAs (siRNAs) that are otherwise barely suitable as therapeutics for inducing RNA interference (RNAi). In preclinical studies on siRNA-based glioma treatment in vivo, various groups of nanoparticle systems, routes of administration and target genes have been explored. Targeted delivery by functionalization of nanoparticles with a ligand for crossing the blood-brain barrier and/or for enhanced target cell transfection has been described as well. Focusing on nanoparticle developments in the last approximately 10 years, this review article gives a comprehensive overview of nanoparticle systems for siRNA delivery into glioma and of preclinical in vivo studies. Furthermore, it discusses various target genes and highlights promising strategies with regard to target gene selection and combination therapies.